Usefulness of non-high-density lipoprotein cholesterol determinations in the diagnosis and treatment of dyslipidemia

American Journal of Cardiology

Volumn 91, Issue 7, 2003, Pages 827-830

  Hirsch, Glenn A ^b   Blumenthal, Roger S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; STATIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANALYTICAL PARAMETERS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DISEASE COURSE; DYSLIPIDEMIA; EDITORIAL; LIPID ANALYSIS; PARTICULATE MATTER; PREDICTION; PRIORITY JOURNAL;

EID: 0344837324     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00018-3     Document Type: Editorial

References (30)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
2. Krauss R.M. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 81:(suppl):1998;13B-17B.
3. Lamarche B., Tchernof A., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., Després J.-P. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 95:1997;69-75.
4. Campos H., Moye L.A., Glasser S.P., Stampfer M.J., Sacks F.M. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA. 286:2001;1468-1474.
5. Blake G.J., Otvos J.D., Rifai N., Ridker P.M. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 106:2002;1930-1937.
6. Hodis N.H., Mack W.J., Krauss R.M., Alaupovic P. Pathophysiology of triglyceride-rich lipoproteins in atherothromobosis clinical aspects . Clin Cardiol. 22:(suppl II):1999;II-15-II-20.
7. Karpe F., Taskinen M.-R., Nieminen M.S., Frick M.H., Kesäniemia Y.A., Pasternack A., Hamsten A., Syvänne M. Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment. Atherosclerosis. 157:2001;181-187.
8. Ruotolo G., Ericsson C.-G., Tettamanti C., Karpe F., Grip L., Svane B., Nilsson J., De Faire U., Hamsten A. Treatment effects on serum lipoprotein lipids, apolipoproteins and low-density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol. 32:1998;1648-1656.
9. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs D.R. Jr, Bangdiwala S., Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79:1989;8-15.
10. Zhang B., Saku K., Ohta T. In vivo metabolism of HDL, apo A-I, and Lp A-I, and function of HDL - a clinical perspective. J Atheroscler Thromb. 7:2000;59-66.
11. Assmann G., Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 70:1992;733-737.
12. Grundy S.M. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 81:(suppl):1998;18B-25B.
13. Ballantyne C.M., Andrews T.C., Hsia J.A., Kramer J.H., Shear C. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol. 88:2001;265-269.
14. Lamarche B., Moorjani S., Lupien P.J., Cantin B., Bernard P.-M., Dagenais G.R., Després J.-P. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebc Cardiovascular Study. Circulation. 94:1996;273-278.
15. Westerveld H.T., Roeters van Lennep J.E., Roeters van Lennep H.W.O., Liem A.-H., de Boo J.A.J., van der Schouw Y.T., Erkelens D.W. Apolipoprotein B and coronary artery disease in women. A cross-sectional study in women undergoing their first coronary angiography. Arterioscler Thromb Vasc Biol. 18:1998;1101-1107.
16. Gotto A.M. Jr, Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., Jou J.Y., Langendörfer A., Beere P.A., Watson D.J., Downs J.R., de Cani J.S. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 101:2000;477-484.
17. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., Steiner E. High apoliopoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study) a prospective study . Lancet. 358:2001;2026-2033.
18. Frost P.H., Havel R.J. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol. 81:(suppl):1998;26B-31B.
19. Cui Y., Blumenthal R.S., Flaws J.A., Whiteman M.K., Langenberg P., Bachorik P.S., Bush T.L. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 161:2001;1413-1419.
20. Pedersen T.R., Olsson A.G., Færgeman O., Kjekshus J., Wedel H., Berg K., Wilhelmsen L., Haghfelt T., Thorgeirsson G., Pyörälä K., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study. Circulation. 97:1998;. 1453-146.
21. Cui Y., Blumenthal R.S., Whiteman M.K., Flaws J.A. The advantages of using non-HDL-C in the diagnosis and treatment of dyslipidemia. Arch Intern Med. 162:2002;109-110.
22. Bittner V., Hardison R., Kelsey S.F., Weiner B.H., Jacobs A.K., Sopko G. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revasculariztion Investigation (BARI). Circulation. 106:2002;2537-2542.
23. Frost P.H., Davis B.R., Burlando A.J., Curb J.D., Guthrie G.P. Jr, Isaacsohn J.L., Wassertheil-Smoller S., Wilson A.C., Stamler J. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation. 94:1996;2381-2388.
24. Grundy S.M. Non-high-density lipoprotein cholesterol level as potential risk predictor and therapy target. Arch Intern Med. 161:2001;1379-1380.
25. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med. 341:1999;498-511.
26. Goldberg A., Alagona P. Jr, Capuzzi D.M., Guyton J., Morgan J.M., Rodgers J., Sachson R., Samuel P. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol. 85:2000;1100-1105.
27. Knopp R.H. Evaluating niacin in its various forms. Am J Cardiol. 86:(suppl):2000;51L-56L.
28. McKenney J.M., McCormick L.S., Schaefer E.J., Black D.M., Watkins M.L. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. 88:2001;270-274.
29. Vega G.L., Grundy S.M. Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy. JAMA. 264:1990;2759-2763.
30. Brown WV, Bays HE, Hassman HA, McKenney J, Chitra R, Hutchinson H, Miller E. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002;144:1036-1043.